Alzheimer Association Refers To Recent Trial Findings For An Experimental Drug As A Breakthrough

Alzheimer Association: This week brought some encouraging updates regarding lecanemab, an investigational treatment that is being used to slow down the progression of Alzheimer’s disease.

On Tuesday, the results of a medication study that was in its third round of testing were published in the New England Journal of Medicine.

According to the findings of the research, lecanemab was able to lower symptoms of the disease by 27%. After taking the medicine, patients who showed early indicators of Alzheimer’s disease showed less cognitive and functional impairment as compared to a group that was given a placebo.

Read More:-

Alzheimer Association Refers To Recent Trial Findings For An Experimental Drug As A Breakthrough

The Oregon and Southwest Washington Chapter of the Alzheimer’s Association expressed their enthusiasm for this piece of news.

It is quite significant. It’s an important step forward in the fight against Alzheimer’s disease. It does in fact make a difference in how the disease progresses. It provides people with more time at a greater level of independence, allowing them to spend more time with their families, makes their own decisions regarding their health care.

And attend one more wedding or one more high school graduation, and so on “According to Chris Madden, who serves as the director of public policy for the Oregon and Southwest Washington Chapter of the Alzheimer’s Association, “

Alzheimer Association Refers To Recent Trial Findings For An Experimental Drug As A Breakthrough
Alzheimer Association Refers To Recent Trial Findings For An Experimental Drug As A Breakthrough

According to Madden, they anticipate an expedited FDA approval for lecanemab around the beginning of January 2023.

Researchers found that lecanemab had various negative effects, including headaches, brain swelling, and bleeding in the brain. Despite the drug’s potential, they found that it had some unwanted effects.

“There are side effects, so we need to be careful about what we’re doing, but if people decide it’s the right path for them, it should be their decision,” Madden said. “It is a serious drug, and it should be done in consultation with your health care provider and with your family.”

At this time, participation in a clinical trial is required in order to get lecanemab. The Alzheimer’s Association is actively working to increase access for anybody who expresses interest in doing so.

Regrettably, the drug will only be effective if it can be administered to patients suffering from Alzheimer’s disease or mild cognitive impairment, and at the present time, the Centers for Medicare and Medicaid Services have a ruling standing that will limit, and to a significant degree limit, patients’ ability to receive this medication.

As a result, we are requesting that individuals step up and campaign for full access. We are confident that the drug will eventually receive full FDA approval; however, based on the results that were published yesterday, we are certain that it is moving in that direction; therefore, all that remains is to ensure that people do have access to the drug “said Madden.

Read More:-

He went on to say that individuals may assist advocates for complete access by getting in touch with their representatives in Congress, emailing the Alzheimer’s Association at www.alz.org, or calling 800-272-3900.

You can visit focushillsboro.com for the latest news. If you have any queries or suggestions can put them in our comment section.

About The Author

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top